The enhancement in wound healing by transforming growth factor-beta 1 (TGF-beta 1) depends on the topical delivery system.
Transforming growth factor-beta 1 (TGF-beta 1) has beneficial effects on wound healing. However, the ideal method for its administration to the wound site remains unknown. Our aim was to analyze the release of TGF-beta 1 from different formulations and to study whether the changes in wound healing by TGF-beta 1 depend on its topical delivery system. For the studies the TGF-beta 1 was incorporated into phosphate-buffered saline, into a polyoxamer gel, into DuoDERM hydroactive paste, and into a poly(ethylene oxide) hydrogel. The release of 125I-labeled TGF-beta 1 from carriers was measured in full-thickness wounds in rats and the healing of the wounds was analyzed by histology and wound area measurements. The TGF-beta 1 was released from all formulations at a different rate and in an active form as determined by growth inhibition assay. Wound size measurements and the analysis on the amount of cellular influx, fibroplasia, and granulation tissue showed that a single dose (1 microgram/wound) of locally administered TGF-beta 1 significantly (P < 0.01) enhanced the wound healing. This effect was most prominent with polyoxamer gel formulation, which provided the most sustained release of TGF-beta 1. Our finding that the enhancement in wound healing by TGF-beta 1 was significantly dependent on the carrier used for its topical delivery to the wound site is novel and shows the importance of using adequate delivery systems when growth factors are used to enhance wound repair.
Puolakkainen
P A
PA
Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington.
Twardzik
D R
DR
Ranchalis
J E
JE
Pankey
S C
SC
Reed
M J
MJ
Gombotz
W R
WR
D000287:Administration, Topical; D000818:Animals; D047070:Bandages, Hydrocolloid; D002021:Buffers; D003102:Colloids; D004337:Drug Carriers; D016503:Drug Delivery Systems; D008297:Male; D009779:Occlusive Dressings; D010710:Phosphates; D011060:Poloxalene; D011092:Polyethylene Glycols; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012867:Skin / Q000293:injuries / Q000473:pathology; D016212:Transforming Growth Factor beta / Q000008:administration & dosage* / Q000627:therapeutic use; D014945:Wound Healing
D002021:Buffers; D003102:Colloids; D004337:Drug Carriers; D010710:Phosphates; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; D011092:Polyethylene Glycols; D011060:Poloxalene